{"entity":{"id":"nct06081244","kind":"trial","name":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)","aka":["ADAPT-TN-III"],"tldr":"A phase 3 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer, run by Women's Cancer Study Group GmbH, now recruiting.","summary":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III). ClinicalTrials.gov record last updated 2026-08-03: recruiting. Enrollment is planned at 348 participants. Primary completion is estimated at 2029-09. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab govitecan, Pembrolizumab. Registered primary measures: pathological complete remission (pCR); invasive disease-free survival rate (iDFS),.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06081244","url":"https://clinicaltrials.gov/study/NCT06081244"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":["trop2"],"drugs":["sacituzumab-govitecan","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-08-03: recruiting. Enrollment is planned at 348 participants. Primary completion is estimated at 2029-09. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06081244","phase":"3","setting":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)","sponsor":"Women's Cancer Study Group GmbH","participation":[{"nct":"NCT06081244","source":"https://clinicaltrials.gov/study/NCT06081244","fetchedAt":"2026-10-07T16:54:11.803Z","studySha256":"d41bec3c7b5a29c40dd58e9b11404bde0a1c8cd797e8ad13b8b9875f29247b10","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-03","leadSponsor":"Women's Cancer Study Group GmbH","collaboratorCount":2,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":348,"enrolmentType":"ESTIMATED","siteCount":43,"recruitingSiteCount":38,"countries":["Germany"]}],"started":"2024-10-10","startedType":"actual","enrolled":348,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06081244/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}